Pfizer stock is undervalued with strong non-COVID growth, robust Q2 2025 results, and strategic R&D pivots. See more on PFE ...

Despite the positive outlook, Pfizer still faces substantive execution risks. The looming challenge of losing exclusivity on certain drugs could impact revenue streams significantly. Moreover, while ...

All of us could use a little more monthly income; it’s not just for retired folks anymore. Considering the state of the economy and the rising household expenses, the idea of receiving a monthly ...

Pfizer Inc. stands out as a robust dividend payer in the big league of medical companies. With a dividend yield of 6.7% and a ...

Three Motley Fool contributors think they've found unstoppable dividend stocks to buy right now. Here's why they picked ...

Looking into the current session, Pfizer Inc. (PFE) shares are trading at $25.84, after a 0.39% increase. Moreover, over the ...

The stock trades at an exceptionally attractive valuation. Pfizer faces some challenges but should continue to survive and ...

Pfizer's payout ratio is around 90% of earnings, which is high for a dividend stock. It reported strong operational growth of ...

Realty Income is a real estate investment trust that has raised its dividend payout 131 times since 1994. Verizon's a ...

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

These three dividend stocks are trading on the cheap given their true valuations. They should be on income investors' radars.

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...